Janssen Research & Development
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Janssen Research & Development sits in the top decile of US sponsors by registered trial count (#57 of 15,742 sponsors by registered trial count).
Janssen Research & Development: 593 sponsored US clinical trials, 68 recruiting.
Janssen Research & Development sponsors 593 registered US clinical trials on ClinicalTrials.gov, 68 of them currently recruiting, and 384 completed. 179 of these trials are in Phase 3-4 (later-stage) and 377 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 25 trials.
Top-decile sponsor footprint
Janssen Research & Development ranks in the top decile of sponsors by registered trial count (#57 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
384 of 436 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
593 total, page 5 of 12
A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus
NCT04882878
A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years
NCT04899336
A Study of JNJ-68179280 in Healthy Participants
NCT04844463
A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy
NCT04836559
A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
NCT04791319
A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795
NCT04844450
A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants
NCT04816513
A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants
NCT04844424
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT04673357
A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants
NCT04616677
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT04630028
A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection
NCT04585789
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
NCT04657224
A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy Participants
NCT04667052
A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis
NCT04633447
Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
NCT04671433
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
NCT04540796
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
NCT04599855
A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
NCT04571697
A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus
NCT04535544
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
NCT04533529
A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
NCT04513912
A Study of Guselkumab in Participants With Active Lupus Nephritis
NCT04376827
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
NCT04532749
A Study of Seltorexant in Healthy Participants
NCT04553042
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection
NCT04439539
A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants
NCT04410094
A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
NCT04523207
A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants
NCT04474210
A Study of JNJ-53718678 in Participants With Hepatic Impairment
NCT04332523
A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection
NCT04508023
Study to Estimate How Common it is to Have Genetic Variants Associated With NAFLD
NCT04494360
A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
NCT04210219
A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants
NCT04394234
A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure
NCT04252287
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
NCT04172675
A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants
NCT04235270
A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants
NCT04223349
A Study for the Identification of Biomarker Signatures for Early Detection of Pulmonary Hypertension (PH)
NCT04193046
A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function
NCT04154774
A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants
NCT04147338
A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis
NCT04021862
A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT04075396
A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine
NCT04132557
A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan
NCT04113551
A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease
NCT04102111
A Study of JNJ-61393215 in the Treatment of Depression
NCT04080752
A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa
NCT04019041
A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations
NCT03955913
First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation
NCT04006301
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 225 |
| Phase 2 | 152 |
| Phase 3 | 173 |
| Phase 4 | 6 |
Therapeutic Areas
What is open in the Janssen Research & Development pipeline
68 recruiting of 593 indexed (11% open); 384 completed (65%).
Phase mix: 179 late (III/IV) vs 377 early (I/II) (early-phase heavy).
Top condition: Healthy (25 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Janssen Research & Development: open-pipeline peers nationwide
Peers matched on 593 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Janssen Research & Development sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 593 trials (± recruiting share)
- Bayer · 591 trials · 4% recruiting
- City of Hope Medical Center · 582 trials · 29% recruiting
- Children's Hospital Medical Center, Cincinnati · 571 trials · 19% recruiting
- Baylor College of Medicine · 616 trials · 15% recruiting
Sponsors near 11% open enrollment (± trial volume)
- Albert Einstein College of Medicine · 11% recruiting · 175 trials
- University of Memphis · 11% recruiting · 35 trials
- Barbara Ann Karmanos Cancer Institute · 12% recruiting · 139 trials
- Children's Mercy Hospital Kansas City · 11% recruiting · 184 trials
Related
What to do with this Janssen Research & Development page
593 registered trials is a research-attention snapshot, not an endorsement of Janssen Research & Development or any single study.
- 68 of Janssen Research & Development's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Janssen Research & Development studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Janssen Research & Development pipeline card: 593 registered trials from official public datasets.Report a data error.